3rd Quarter - Report

MASIMO CORPORATION for MASIMO CORPORATION

Period 3rd Quarter 2019 Filed Oct 21, 2019 Signed by Catherine Meier

Official filing
Firm
MASIMO CORPORATION
Client
MASIMO CORPORATION
Income
—
Expenses
$80,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Support for continuous monitoring of patients taking opioids; S.1227, HR 2376 - Prescription Pricing for the People Act of 2019; S 1895: Lower Health Care Costs Act; Government Purchasing Organizations (GPOs) and anticompetitive behavior; H.R. 2740: Fiscal Year 2020 Labor-Health and Human Services, Education, Defense, State-Foreign Operations, and Energy and Water Development spending bills: Proposed study of continuous monitoring for patients taking opioids.

LobbyistCovered position, as disclosed
CATHERINE MEIER —
PAUL ORDAL —

Contacted: Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2376 (116th), S. 1227 (116th), H.R. 2740 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.